Inventia Healthcare recalled more than 13,000 bottles of chlorthalidone tablets due to failed dissolution specifications, prompting a Class II classification from the Food and Drug Administration on September 17. The nationwide recall affects specific 25-milligram prescription lots manufactured by the company, following an initial recall initiated by the firm back in June.
Understanding the Chlorthalidone Recall and Dissolution Failure
The recall affects 100-tablet bottles of chlorthalidone tablets, USP, 25 mg, labeled as Rx only and manufactured by Inventia Healthcare Limited. According to the FDA, proper dissolution means the active ingredient dissolves adequately from its dosage form so the body can absorb it. When medication fails these specifications, patients may not absorb enough of the active compound, reducing the drug’s effectiveness in treating high blood pressure and preventing related health conditions.
Chlorthalidone functions as a diuretic, or water pill, which directs the kidneys to shed excess salt and water. This mechanism lowers blood pressure and minimizes fluid retention, which helps prevent organ damage that can lead to heart attacks, heart disease, heart failure, strokes, kidney damage, and vision-impacting eye damage.
FDA Classification and Timeline of Inventia Healthcare Recalls
The FDA classified the September action as a Class II recall. This classification indicates that exposure to the affected product may cause temporary or medically reversible health issues, though the probability of serious adverse effects remains remote.
Inventia Healthcare first initiated recalls for certain lots of the diuretic in June. The company followed with a separate recall involving an additional lot on September 3. Federal regulators subsequently classified both the initial June action and the September expansion under the Class II designation.
Steps for Patients Holding Affected PresCRIPTIONS
Patients who possess the medication should check their prescription bottle labels for the exact matching details: chlorthalidone tablets, USP, 25 mg, packaged in 100-tablet bottles, designated as Rx only, and manufactured by Inventia Healthcare Limited. Anyone unable to confirm all of these label details should contact their pharmacist for assistance immediately.
The FDA advises patients to contact their healthcare provider right away rather than making independent decisions about stopping their treatment. Individuals experiencing any illness should report those symptoms to their doctor immediately.
Quick Facts on the Inventia Healthcare Recall
- Drug Name: Chlorthalidone tablets, USP, 25 mg
- Package Size: 100-tablet bottles, Rx only
- Manufacturer: Inventia Healthcare Limited
- Scope: More than 13,000 bottles in the September recall
- Reason: Failed dissolution specifications
- FDA Classification: Class II (classified September 17)
Common Questions About the Blood Pressure Medication Recall
Why were the chlorthalidone tablets recalled?
Inventia Healthcare recalled the medication because the tablets failed dissolution specifications, meaning the body might not absorb enough of the active ingredient for the drug to work properly.
What does a Class II recall mean?
According to the FDA, a Class II recall means exposure to the product may cause temporary or medically reversible health consequences, with a remote probability of serious harm.
How many bottles are affected by the September recall?
The September action involves more than 13,000 bottles of the blood pressure medication.
What should I do if I find the recalled medication in my medicine cabinet?
Contact your healthcare provider immediately before stopping the medication, and consult your pharmacist to verify your prescription label details.
Worth a look